Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4903068 | PMC |
| http://dx.doi.org/10.1093/schbul/sbw048 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting.
J Mark Access Health Policy
September 2017
Department of Public Health, Aix Marseille University, Marseille 5, France.
: Adverse event (AE) reporting in clinical trials does not fully capture the patient-level perspective and comparing tolerability across treatments or among studies is difficult. : This study was designed to develop a treatment tolerability index algorithm that combines AE reporting with physician- and patient-level AE information into a global burden score to allow comparison of the overall tolerability of antipsychotic medications used in treating schizophrenia. : Data from a 4-arm, placebo-controlled clinical trial were used in the proposed tolerability index algorithm.
View Article and Find Full Text PDFBifeprunox versus placebo for schizophrenia.
Cochrane Database Syst Rev
October 2016
Medical School, University of Nottingham, 6 Rolleston Drive, Nottingham, UK, NG7 1JT.
Background: Bifeprunox is a novel antipsychotic drug designed to treat schizophrenia. However, research into the drug was ceased in 2009 due to rejection of licence to go to market by the US Food and Drug Administration (FDA), who could not approve the drug for acute or long-term symptoms of schizophrenia because more research was required to demonstrate convincing effects "beyond those already achieved" with currently licenced drugs. There were also concerns expressed over one death of a person whilst on the drug.
View Article and Find Full Text PDFBifeprunox vs Placebo for Schizophrenia.
Schizophr Bull
July 2016
Institute of Mental Health, University of Nottingham, Nottingham, UK.
The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis.
J Clin Psychiatry
October 2010
University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.
Context: In the Clinical Antipsychotic Trials of Intervention Effectiveness, atypical antipsychotics (AAPs) were found to be associated with weight gain and impairment of glucose metabolism. While metformin has been shown to attenuate weight gain and insulin resistance, not all studies have shown a benefit in the reduction of antipsychotic-induced weight gain and insulin resistance.
Objective: To characterize metformin's impact on anthropometrics and insulin resistance in patients taking AAPs.
Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
Drugs
January 2009
Pharmacy Department, Maudsley Hospital, London, UK.
Since the introduction of a group of atypical antipsychotics in the 1990s, there has been a decline in the rate of new antipsychotics being introduced into clinical practice. However, with increasing safety and efficacy concerns over currently available drugs and a dearth of options available for atypical depot formulations, there is a considerable need for the development of new formulations and agents. This review examines the profile of seven antipsychotic drugs currently in the premarketing stage of development and summarizes their mechanism of action, clinical potential and safety.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!